From Plate to Patient: A Systematic Review of Food‐Related Campylobacteriosis Case Reports Authors: Minoo Moghimani, Fateme Asadi Touranlou, Lida Jarahi, Asma Afshari Published: 2026 ABSTRACT ABSTRACTBackground and AimsCampylobacteriosis, primarily caused by Campylobacter jejuni, C. coli, and C. fetus, remains the leading bacterial cause of foodborne gastroenteritis globally, with increasing incidence in both developed and developing nations.MethodsThis systematic review synthesizes case reports of food‐related campylobacteriosis published between January 2000 and September 2024, retrieved from Web of Science, PubMed, ScienceDirect, Scopus, and Google Scholar. From 9407 identified articles, 63 case reports (66 individual cases) were included following PRISMA guidelines.ResultsThe analysis reveals a rising global trend in campylobacteriosis, with the highest case reports from the United States (20.9%) and Japan (20.9%), predominantly linked to poultry consumption. Cases were more frequent in males (74.6%) than in females (25.4%), with a median age of 34.5 years. Common symptoms included diarrhea (82.9% in immunocompetent individuals), vomiting, nausea, and fatigue, with severe complications such as myocarditis, bacteremia, and meningitis observed in immunocompromised patients. C. jejuni was the most prevalent species (54%), followed by C. coli (12%) and C. fetus (25%).ConclusionThese findings underscore the urgent need for enhanced global surveillance, improved food safety practices, and targeted public health interventions to mitigate the burden of campylobacteriosis, particularly for high‐risk groups and poultry‐related transmission. Introduction The Campylobacter genus was created by changing the name of Vibrio fetus to Campylobacter fetus in 1993. Kaakoush et al. [1] Campylobacter is made from two Greek words, “Campylo” meaning curved and “Bacter” meaning rod [2]. Species of this bacteriam are common inhabitants of the digestive tract of animals [3]. Campylobacter is a Gram‐negative, rod‐shaped, flagellated, microaerophilic bacterium [1]. Most Campylobacter species have motile bacterial cells that possess a flagellum at one or both ends, enabling them to move in a corkscrew‐like manner [4]. The Campylobacter genus is currently a part of the Campylobacteraceae family and comprises 32 officially recognized species along with 9 subspecies [5]. Campylobacter is the most common bacterial species causing food‐borne gastroenteritis worldwide [6]. Currently, the most significant species in the genus is C. jejuni, which is a primary agent of bacterial gastroenteritis in humans. Its global prevalence surpasses that of widely recognized pathogens like Escherichia coli, Shigella, and Salmonella, which are known to cause acute gastrointestinal infections [7, 8]. A closely related species to C. jejuni is C. coli, which is responsible for causing between 1% and 25% of all cases of diarrheal diseases associated with Campylobacter [5, 9]. Figure 1 summarizes the primary transmission routes of Campylobacter to humans. Most infections result from consuming raw or undercooked poultry or cross‐contaminated foods, as reported by the Centers for Disease Control and Prevention [10]. Other transmission modes include consumption of contaminated seafood, meat, or produce, contact with animals, and ingestion of untreated water [6]. For example, infections may occur when a cutting board used for raw chicken is inadequately cleaned before preparing salads or fruits [11]. Contact with dog or cat feces and, rarely, transfusion of contaminated blood can also transmit the bacteria [12]. Modes of Campylobacter transmission to humans. Campylobacteriosis typically presents with diarrhea and abdominal pain in 80% of cases, with fever, headache, and myalgia affecting approximately 50% of patients; symptoms like bloody stools or vomiting are less common [13, 14]. The disease is generally self‐limiting, with a 24–72‐h incubation period and an average duration of 6 days. Infections can occur with a low infectious dose, as few as 360 CFU, though mathematical models suggest 9 × 104 CFU/mL yields the highest incidence [13, 14]. The frequency and occurrence of campylobacteriosis have risen in both developed and developing nations in the past decade. While campylobacteriosis affects all age groups, it peaks in children and young adults, with a low fatality rate of 0.05 per 1000 infections. Anvarinejad et al. [15]. However, bacterial translocation can lead to severe extraintestinal complications, including arthritis, hepatitis, peritonitis, meningitis, endocarditis, sepsis, pericarditis, and bacteremia [1, 15, 16, 17, 18]. Notably, Campylobacter infection is a leading precursor to Guillain–Barré syndrome, a neurological disorder causing acute polyneuropathy, particularly in immunocompromised individuals, the elderly, or children [19, 20]. This condition mainly occurs in people with a weak immune system, the elderly, or children [13]. In hyperendemic regions with limited resources, high childhood transmission may result in asymptomatic cases and progressive immunity in older individuals [2]. Identifying Campylobacter infection sources is challenging due to their sporadic nature, the role of cross‐contamination, and difficulties in bacterial isolation, as Campylobacter is sensitive to desiccation, extreme temperatures, and is unable to multiply outside the host. Identifying Campylobacter infection sources is challenging due to their sporadic nature, the role of cross‐contamination, and difficulties in bacterial isolation, as Campylobacter is sensitive to desiccation, extreme temperatures, and unable to multiply outside the host [18, 21, 22, 23]. However, Campylobacter can adapt to the environment, survive, show resistance to air and starvation, and find a way to enter the host's body. Fortunately, nowadays, molecular methods for identifying Campylobacter species have been successful. However, rapid, specific, and standard methods of detection and counting need further studies [18]. Campylobacteriosis imposes a significant economic burden globally, with annual costs estimated at €2.4 billion in Europe and $2.9 billion in the United States [24]. Finally, it should be noted that the burden of campylobacteriosis is high, and a lot of money is spent on it every year (including doctors' fees, medicine, etc.). Therefore, this article intends to conduct a systematic review of the case reports of food‐related Campylobacteriosis to investigate its trend globally. Materials and Methods Search Strategy A systematic review was conducted at PubMed, Science Direct, Scopus, Web of Science, and Google Scholar to identify all studies published between January 2000 and September 2024 with the query of ((((((((campylobacteriosis) OR Campylobacter) AND outbreak) OR gastroenteritis) OR enteritis) OR poultry) OR zoonoses) OR raw food) OR case report. The searched keywords were extracted from the Medical Subject Headings (MeSH) thesaurus. EndNote X7 software was used to enter all found citations. Duplicate articles were removed, and abstracts of the remaining articles were received for further study. References from retrieved articles were reviewed to identify additional relevant studies. The review adhered to PRISMA guidelines (Figure 2). Flow diagram of the study selection process following the PRISMA. Inclusion and Exclusion Criteria The selection of studies was based on the following criteria: 1.Full text available2.Published text in the English language3.Articles that provided original data (case reports)4.published between 2000 and 20245.Case reports indicate suspicious contact with pets or farm animals or consumption of suspicious food. 1.Full text available Full text available 2.Published text in the English language Published text in the English language 3.Articles that provided original data (case reports) Articles that provided original data (case reports) 4.published between 2000 and 2024 published between 2000 and 2024 5.Case reports indicate suspicious contact with pets or farm animals or consumption of suspicious food. Case reports indicate suspicious contact with pets or farm animals or consumption of suspicious food. Exclusion criteria included review articles, experimental studies, conference proceedings, case‐control studies, cohort studies, clinical trials, and books. Article Selection Minoo Moghimani (M. M.) and Fateme Asadi Toranlou (F. A. T.) conducted the initial search and screened articles based on titles and abstracts. Articles meeting the inclusion criteria were thoroughly evaluated. Asma Afshari (A. A.) verified the selected articles. M. M. extracted data from the selected articles, which were then reviewed by Lida Jarahi (L. J.), A. A., and F. A. T. for accuracy. Data Extraction A standardized data extraction form was developed in Excel. Extracted data included the title, first author, publication year, country of origin, participant age, gender, type of food or animal exposure, and symptoms reported in the articles. Statistical Analysis Descriptive statistics, including mean and standard deviation (SD) for continuous parametric data, and median and interquartile range (IQR) for nonparametric data, were presented. For categorical data, frequency and percentage were utilized. The Kolmogorov–Smirnov test assessed normality. Quantitative variables were analyzed using either Student's t‐test or Mann–Whitney U test, depending on the distribution's normality; the chi‐square test or Fisher's Exact Test was used to determine associations between categorical variables. Binary logistic regression was conducted to identify risk factors for positive cases, with the odds ratio (OR) reported along with a 95% confidence interval (CI). Data analysis was performed using SPSS 25, with a significance threshold set at p < 0.05 [25, 26]. Results and Discussion In this systematic review of campylobacteriosis case reports, cases were categorized into two groups: immunocompetent (cases without a history of prior diseases) and immunocompromised (cases with underlying health conditions, such as cancer or meningitis). Characteristics of Study Samples and Campylobacter Cases We identified 9407 unique records through the search strategy. After title and abstract screening, 391 records were considered potentially relevant, and their full‐text reports were retrieved for eligibility assessment (Figure 2). Based on the inclusion criteria, 62 records (representing 66 individual patient cases) were included in the review (Supporting information S1_File). A comprehensive summary of included publications is presented in Table 1a (immunocompetent cases) and Table 1b (immunocompromised cases). Table 1aA comprehensive summary of all articles reporting campylobacteriosis in people who had no history of other diseases.AuthorYearConturyFoodAnimalGenderAgeDiarrheaVomitingAbdominal painNauseaHeadachesFeverFatigueChillsCampylobacterNakagawa, Nishihara [38]2016JapanPNM5PNPNNPNN jejuni Chantzaras et al., [39]2021GreecePNW13PNPNpPNN jejuni Pena, Fishbein [40]2007USAPNM16PpPNNPNP jejuni Ayyildiz et al., [41]2018TurkeyPNM17PpPpNNNN jejuni Hessulf et al., [42]2016SwedenPNM23PNPNNPNP jejuni PNM24PNPNNPNP jejuni Kano [43]2021JapanPNM29PNNNNPNN jejuni Cunningham & Lee, 2003)2003CanadaPNM30PNNNNPNP jejuni Ikeda et al., [44]2019JapanPNW35NNNNPNNN fetus Ishihara et al., [45]2018JapanPNW48NNNNPNNN fetus Chávez et al., [46]2016EcuadorPNW49NNNPNPNP fetus Fornefett et al., [47]2018GermanyPPM50PNNPNNNNOther speciesSanagawa et al., [48]2020JapanPNM51NNNNPPNN jejuni Tan et al., [49]2016UKPNM57PNNNNPNN—Krause et al., [50]2002AustriaPNM72PNNNNPNNMulti speciesGorkiewicz et al., [51]2002AustriaNPW88PpPNNNNNMulti speciesAbbasi, Ghaznavi‐Rad [52]2019IranPNM1PNPNNPNNMulti speciesRafael et al., [53]2016PortugalNPW17daysPNNNNpNN jejuni Mizuno et al., [54]2021JapanPNW2 daypNNNNNNN jejuni Campagnolo et al., [55]2016USANPW35–44PNPPNPNP jejuni NPM45–54PPNPNPNN—NPW5–14PPNPNPNN jejuni Kuperman‐Shani et al., [56]2015IsrailPNW27NNNNPPNN coli Kobayashi et al., 2014)2014JapanPNM25PNNNNPNN—Kratzer et al., [57]2010AustriaPNM19PNPPNNNN jejuni Adrianza et al., [58]2023USAPNM40PNPNNPPP coli Chang, Kao [59]2022TaiwanNPM28PPNNPPNN—Marconi et al., [60]2023ItalyNNW3‐month‐oldPNNNNPNN jejuni Medic et al., [61]2024SerbiaNNM68NNPNNNNN fetus Ozaka et al., [62]2023JapanPNM35PNPNNPNN jejuni Quinaux et al., 2023)2022FrancePNM17PPPNNNNN coli Takemoto et al., [63]2022JapanPNM21PNNNNPpN jejuni 2019PNM19PNNNNPpN jejuni Vera et al., [64]2024EcuadorPNM32PPNNNPNN coli (Francis et al., 2023)2023USAPNM63PPNNNPNN—Zulqarnain et al., [65]2022ChinaPNM59PNPNNPNP jejuni Chu et al., [66]2022TaiwanPNM15PNPNNPNN—Dobrović et al., [67]2019CroatiaNPM67NNNNNPPN fetus Hassan et al., [68]2022UKPNMmiddle‐agedPNPNNPPN jejuni Kirk et al., [69]2023DenmarkNNM79PNPNNPNN jejuni Note: a In this column P represent healthy group, people who had no history of any diseases and N represent unhealthy group, people who had a secondary diseaseAbbreviations: M = Man, N = Negative, P = Positive, W = Woman‐ means Not Reported.John Wiley & Sons, Ltd. A comprehensive summary of all articles reporting campylobacteriosis in people who had no history of other diseases. Note: a In this column P represent healthy group, people who had no history of any diseases and N represent unhealthy group, people who had a secondary disease Abbreviations: M = Man, N = Negative, P = Positive, W = Woman‐ means Not Reported. Table 1bA comprehensive summary of all articles reporting campylobacteriosis in people who had a secondary disease.AuthorYearConturyFoodAnimalGenderAgeDiarrheaVomitingAbdominal painNauseaHeadachesFeverFatigueChills Campylobacter Ali et al., [70]2020USAPNM73NNNNNNNN jejuni Cambier et al., [16]2018BelgiumPPM57PNNPPNPN coli Elford et al., [71]2021TasmaniaPNM29PNNNNNNN jejuni Kiyasu et al., [72]2017JapanPNM62NNNNNNPN fetus Suarez et al., [73]2019USAPNM63PNPNNNNP coli Sharma et al., [2]2022USAPNM48PNPNNNNN—Seong et al., [3]2021KoreaNPM28NNNNNNPN fetus Reid et al., [37]2016USAPNM70sNNNNNNPP fetus Nishikubo et al., [74]2021JapanPNW64NNNNNNPN fetus Colosimo et al., [75]2015ItalyNNM53NNPPNNPN jejuni Flipse et al., [76]2020NetherlandsNPM42PNPNNNNNMulti speciesIraola et al., [77]2013UruguayNNM64NNNNNNNN fetus Reda, Mansell [78]2005New ZealandPNM20PNPNNNPN—Clark, Murray [79]2020UKPNW58PNPNNNNN coli Neves‐Maia et al., [36]2022PortugalPNM34PNNNNNPN jejuni Mortensen et al., [34]2020DenmarkPNM22PNPNNNPN—Suy et al., [80]2010FrancePNM75NNNNNNPP fetus Hwang et al., [81]2022USAPNM80sPPPPNNNN—Westenfield et al., [35]2020USAPNW57PPPNNNNN jejuni Martínez‐Balzano et al., [82]2011USAPNM28PNNNPNPP fetus Edbert et al., [83]2023IndonesiaNPMeight‐month‐oldNNNNNNPN jejuni Asatori, Shimada [84]2022JapanPNW22PPPNpNPP jejuni Azar et al., [85]2023USAPNM29NNNNNNPN fetus Mnif et al., [86]2022TunisiaNPW54NNNNPNPN fetus Marconi et al., [60]2023ItalyNNM—PNNNNNNN jejuni Su et al., [87]2021TaiwanPNM19NNNNNNPN jejuni Note: In this column, P represents the healthy group, people who had no history of any diseases and N represents the unhealthy group, people who had a secondary disease.Abbreviations: M = Man, N = Negative, P = Positive, W = Weman, ‐ means Not ReportedJohn Wiley & Sons, Ltd. A comprehensive summary of all articles reporting campylobacteriosis in people who had a secondary disease. Note: In this column, P represents the healthy group, people who had no history of any diseases and N represents the unhealthy group, people who had a secondary disease. Abbreviations: M = Man, N = Negative, P = Positive, W = Weman, ‐ means Not Reported Patient Demographics Table 2 summarizes demographic and epidemiological factors related to campylobacteriosis prevalence. The mean age of patients was 38.4 years (SD = 23), with a range of 3 months to 88 years. Table 2Distribution of different demographic and epidemiologic factors in the occurrence of campylobacteriosis.Variablea Campylobacteriosis p valued Immunocompetentb Immunocompromisedc Age33.43 (± 23.47)46.46 (± 22)0.02SexMale29 (70.7%)21 (80.8%)0.4Female11 (29.3%)5 (19.2%)Relationship with the food source31 (75.6%)19 (73.1%)> 0.99Contact With an Animal7 (17.1%)6 (20%)0.75Species Of Campylobacter C. Jejuni 22 (62.9%)9 (40.9%)0.13 C. Coli 4 (11.4%)3 (13.6%) C. Fetus 5 (14.3%%)9 (40.9%)Multi species3 (8.6%)—Other species1 (2.9%)1 (4.5%)Campylobacteriosis manifestationsDiarrheas34 (82.9%)14 (53.8%)0.01Vomiting9 (22%)3 (11.5%)0.27Abdominal Pain18 (43.9%)10 (38.5%)0.66Nausea7 (17.1%)3 (11.5%)0.53Headache6 (14.6%)4 (15.4%)0.93Fever31 (75.6%)16 (61.53%)0.25Fatigue5 (12.2%)16 (61.5%)< 0.001Chills8 19.5%)5 (19.2%)0.97 a Quantitative variables were reported as mean (± SD) and qualitative variables were reported as frequency (%). b Immunocompetent group had no history of any disease that was mentioned in the article. c Immunocompromised group had secondary diseases or any history of illness. d Student's t‐test or Mann–Whitney U test were used for quantitative variables, and Chi‐Square or Fisher's Exact Test were used for qualitative variables.John Wiley & Sons, Ltd. Distribution of different demographic and epidemiologic factors in the occurrence of campylobacteriosis. Quantitative variables were reported as mean (± SD) and qualitative variables were reported as frequency (%). Immunocompetent group had no history of any disease that was mentioned in the article. Immunocompromised group had secondary diseases or any history of illness. Student's t‐test or Mann–Whitney U test were used for quantitative variables, and Chi‐Square or Fisher's Exact Test were used for qualitative variables. Immunocompetent patients were significantly younger than immunocompromised patients (p value = 0.02), indicating that younger individuals were more likely to contract campylobacteriosis without prior health conditions. However, in a subgroup analysis restricted to adults, no significant age difference was observed between the immunocompetent and immunocompromised groups (mean age 44 years [SD = 19] vs. 48 years [SD = 20], p value = 0.42). In the immunocompromised group, most cases involved adults aged 19–80, except for one 8‐month‐old infant and one case with unreported age. Campylobacteriosis cases were reported across all age groups, with higher prevalence among children and the elderly, consistent with prior studies [27, 28]. The presence of underlying illnesses increased the risk of campylobacteriosis in adulthood. Significantly more males (50, 74.6%) than females (16, 25.4%) had reported cases of campylobacteriosis. However, no significant gender difference was observed between the immunocompetent and immunocompromised groups (p value = 0.4). Previous research, including a meta‐analysis by Green et al., confirmed higher incidence rates in males, particularly among infants and young children [29, 30]. This suggests gender may influence campylobacteriosis incidence, though the underlying mechanisms remain unclear, warranting further investigation. Sources of Infection According to the reports, the important sources of Campylobacter infection include contact with live poultry, consumption of poultry meat, drinking untreated water, and contact with pets and other animals. The results of our statistical analysis showed that there was no significant difference in the source of food infection between the two groups with intact and immunocompromised systems (p value > 0.99). The results were similar for the source of animal infection (p value = 0.75). However, in general, according to Figure 3, the food source played a more important role in the occurrence of campylobacteriosis than animals, and in line with other studies, consumption of contaminated poultry and meat had the highest risk [27, 28, 31, 32]. Sources of Campylobacter infection: Food versus Animal and Breakdown of Food Sources. Epidemiological Trends The prevalence of Campylobacter cases was notably high in 2022, reaching16.4%. Before this year, the number of reported cases was relatively low, with no cases reported in the years 2000, 2001, 2004, 2006, 2008, 2009, and 2012, no cases were reported (Figure 4). Since then, the number of reported cases has increased and at least one case has been reported in all subsequent years. Among 67 cases, the largest number was reported in the United States, 14 (20.9%) of America, and 14 in Japan (20.9%) of Asia (Figure 5). Distribution of campylobacteriosis incidence by year. Distribution of campylobacteriosis incidence by country. In keeping with earlier research, our findings indicate that the prevalence of campylobacteriosis has risen worldwide. Since there is currently no vaccine to prevent this illness and the only effective treatment is the use of antibiotics, which can lead to antibiotic resistance, Campylobacteriosis infection is a public health emergency. It appears that the only feasible approach to preventing this infection is to educate the public about the need to follow personal safety precautions, such as washing hands after handling animals, and to refrain from eating any raw or undercooked meat, particularly chicken [27]. While it is anticipated that the incidence of campylobacteriosis would be higher in developing countries, research indicates that the rates are rising in both developing and developed nations. Our study found that from 2000 to 2024, the highest number of reported campylobacteriosis cases occurred in the developed countries of the United States and Japan. This may reflect better diagnostic and reporting capabilities rather than true differences in disease prevalence, potentially underrepresenting the burden in resource‐limited settings. Additionally, developed nations are more likely to invest in monitoring and reporting Campylobacter infections due to their greater resources and advanced facilities for isolating and identifying the pathogen. In contrast, developing countries, despite potentially facing a higher burden of this infection, often contend with more pressing health issues that result in higher mortality rates. Consequently, we cannot definitively conclude that lower reported cases in other regions indicate a lesser threat from Campylobacter or that it poses a more significant health risk in the United States and China [27, 28, 31, 32]. Diversity of Campylobacter Species No significant differences were observed in Campylobacter strains between the immunocompetent and immunocompromised groups (Table 2). Overall, C. jejuni (54.0%), C. fetus (25.0%), and C. coli (12.0%) were the most frequently reported species (Figure 6). These findings align with prior studies indicating that C. jejuni and C. coli cause over 95% of human campylobacteriosis cases [27, 28, 31, 32, 33]. The most common samples for Campylobacter isolation were stool, blood, and cerebrospinal fluid. Prevalence of Campylobacter species linked to campylobacteriosis. Clinical Manifestations We analyzed the clinical manifestations of campylobacteriosis in immunocompetent and immunocompromised individuals (Table 2). Immunocompetent individuals primarily experienced diarrhea (82.9%, p < 0.01), while immunocompromised individuals more commonly reported fatigue (61.5%, p < 0.001). This difference likely reflects a stronger immune response in immunocompetent individuals, leading to pronounced gastrointestinal symptoms, whereas immunocompromised individuals, with a diminished immune response, primarily exhibit fatigue and lethargy. Secondary Consequences of Campylobacteriosis Campylobacteriosis is typically a self‐limiting illness, with symptoms lasting anywhere from 3 to 10 days. The incubation period generally falls between 2 and 5 days, although it can range from 1 to 11 days. While diarrhea is the most prevalent symptom associated with Campylobacter spp. infection, the clinical presentation can vary widely, encompassing everything from asymptomatic cases to severe systemic illness, bacteremia, localized infections, and various complications. Notably, some of the recognized secondary effects of Campylobacteriosis include cardiac complications, Guillain–Barré Syndrome (GBS), Reactive Arthritis (REA), and Irritable Bowel Syndrome (IBS) [27, 28, 31, 32, 33, 34]. In the case reports analyzed in this study, the majority of secondary effects associated with campylobacteriosis were linked to cardiac complications. These included conditions such as acute myoepicarditis [35], primiocarditis [34], pericarditis [36], and endocarditis [37]. Limitations This systematic review has several limitations that warrant consideration. First, the probable nature of identified infection sources, such as contaminated food or animal contact, could not be definitively confirmed due to the absence of microbiological analysis of suspected sources in most cases. Second, the predominance of reports from developed countries (e.g., the United States and Japan) may reflect better diagnostic and reporting capabilities rather than true differences in disease prevalence, potentially underrepresenting the burden in resource‐limited settings. Third, the lack of comprehensive patient demographic data and clinical details in some articles limited the depth of subgroup analyses, particularly regarding socioeconomic factors or detailed dietary histories. Conclusion Campylobacteriosis, driven primarily by C. jejuni and C. coli, represents a significant global public health challenge due to its rising incidence and substantial economic burden. This systematic review highlights the predominant role of contaminated poultry and meat in transmission, with males and severe complications disproportionately affecting immunocompromised patients. The concentration of reported cases in developed nations underscores the need for standardized global surveillance systems to capture the true burden of campylobacteriosis, particularly in low‐resource settings. To reduce incidence, public health strategies should prioritize education on safe food handling, especially for poultry, and promote rigorous hygiene practices to prevent cross‐contamination. Future research should focus on developing rapid, standardized diagnostic tools and exploring vaccine development to address antibiotic resistance concerns. Enhanced international collaboration and investment in food safety infrastructure are critical to mitigating the global impact of this preventable foodborne disease. Author Contributions Fateme Asadi Touranlou and Minoo Moghimani: conceptualization, writing – original draft. Lida Jarahi: methodology, conceptualization, and editing. Asma Afshari: supervision, visualization and editing. All authors have read and approved the final version of the manuscript. Asma Afshari had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. Ethics Statement The study protocol was approved by the Ethics Committee of Mashhad University of Medical Sciences (IR. MUMS. MEDICAL. REC.1402.025) after obtaining the required permit for the research. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The lead author, Asma Afshari, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Supporting information Supporting File: hsr272197‐sup‐0001‐S1_File.xlsx.